Porvair Filtration Group, a world leader in filtration and separation technology, has announced further expansion of resources at its Ashland, VA facility to cope with increased North American demand for porous plastics.
Available in sheet, tube, and almost any 3 dimensional molding in a range of pore sizes (10-100 micron) - Porvair Filtration Group offers a range of high performance Vyon™ and BioVyon™ sintered porous plastics that are FDA and WRAS approved, easily cleanable, strong, rigid and self-supporting with a long life expectancy and high resistance to chemicals. These materials can be supplied as OEM products or can be integrated and packaged into finished products.
Tom Liddell, Managing Director of Porvair Filtration Group commented "Following a recent merger of competitive suppliers and consequent rationalization of their product offerings - Porvair expanded its US manufacturing facilities and technical support staff to cope with the increasing demand to provide porous plastic components and to offer users a real alternative". He added "Porvair Vyon™ and our new NanoPure BioVyon™ porous plastics have been qualified in a growing number of applications at US companies where supply chains may have recently been threatened or prices increased".
Porvair Filtration Group is at the forefront of new material development and products for the medical, pharmaceutical and life science markets - progressive industries which aim to improve people's lives. The company's range of Vyon™ and BioVyon™ sintered porous plastic materials and products have been developed using novel technologies to help advance the achievable technical boundaries in these markets. Precisely manufactured using state-of-the-art techniques, in Porvair's ISO accredited production facilities, Vyon™ and BioVyon™ materials exhibit very low particle shedding, low extractables and low bio burden.
To discuss your filtration or separation application please contact Porvair Filtration Group on +1-804-550-1600, or email info@porvairfiltration.com.
No comments:
Post a Comment